Ran Nussbaum

CIK 1609805 · last filed 2026-06-05

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$134.21M

Companies

6

Total Filings

53

Lifetime Open-Market Net

$25.28M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LBRX Director 1,411,681 $28.42 $40.12M $15.00M 3 2026-06-05
KROS Director 160,512 $10.15 $1.63M $25.00M 9 2025-06-11
URGN Director 1,437,169 $29.72 $42.71M $0 11 2023-02-28
ELOX Director 3,679,797 $13.52 $49.75M $13.21M 9 2022-06-17
Prevail Therapeutics Inc. (PRVL) Delisted Director $0 1 2020-06-19
Kite Pharma, Inc. (KITE) Delisted Director 7,880 -$27.94M 6 2017-06-22

Recent Filings · Page 4 of 6

53 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2019-09-16 Exer (X) +114,286 $200.0K
2019-07-01 Buy (P) +307,692 $3.00M
2019-06-26 ELOX Buy (P) +200,000 $1.80M EDGAR
2019-06-05 URGN Grant (A) $0 EDGAR
2019-05-30 ELOX Grant (A) $0 EDGAR
2019-05-29 ELOX Grant (A) $0 EDGAR
2019-05-15 Grant (A) $0
2018-10-22 Buy (P) +181,818 $1000.0K
2018-06-19 ELOX Grant (A) $0 EDGAR
2018-05-25 Other (J) +6,608,000 $0
Showing 3140 of 53
Page 4 of 6
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.